KRYS
Krystal Biotech Inc
NASDAQ: KRYS · HEALTHCARE · BIOTECHNOLOGY
$312.88
-2.21% today
Updated 2026-06-05
Market cap
$9.37B
P/E ratio
42.57
P/S ratio
22.46x
EPS (TTM)
$7.47
Dividend yield
—
52W range
$128 – $331
Volume
0.3M
WallStSmart proprietary scores
65
out of 100
Grade: B
Buy
Investment rating
8.3
Growth
A9.0
Quality
A+9.0
Profitability
A+4.7
Valuation
C4/9
Piotroski F-Score
Moderate
8.0
Altman Z-Score
Safe zone
—
Industry rank
—
View all highly rated stocks (75+) →199 stocks currently score above 75
Price targets
Analyst target
$324.11
+3.59%
12-Month target
$205.44
-34.34%
Intrinsic (DCF)
—
Margin of safety
—
0 Strong Buy10 Buy1 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Altman Z 8.02 — safe zone
+ Profit margin 53.90% — above average
+ Free cash flow $73.23M — positive
+ Revenue growth 31.90% QoQ
+ Debt/equity 0.01x — low leverage
Risks
- P/E 42.57x — expensive valuation
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM | 2026 (E) |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $50.70M | $290.51M | $389.13M | $417.30M | $552.0B |
| Net income | $-139.97M | $10.93M | $89.16M | $204.83M | $55.93M | — |
| EPS | — | — | — | — | $7.47 | $8.50 |
| Free cash flow | $-153.55M | $-100.60M | $119.18M | $188.91M | $73.23M | — |
| Profit margin | — | 21.56% | 30.69% | 52.64% | 53.90% | — |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-06-04 | KRISHNAN, SUMA | Sale | 12,729 | $307.81 |
| 2026-06-04 | KRISHNAN, SUMA | Sale | 3,803 | $308.89 |
| 2026-06-04 | KRISHNAN, SUMA | Sale | 2,801 | $309.95 |
Peer comparison
Smart narrative
Krystal Biotech Inc trades at $312.88. representing a P/E of 42.57x trailing earnings. Our Smart Value Score of 65/100 indicates the stock is good. The company scores 4/9 on the Piotroski F-Score. With an Altman Z-Score of 8.02, it sits in the safe zone. TTM revenue stands at $417.30M. with profit margins at 53.90%.
Frequently asked questions
What is Krystal Biotech Inc's stock price?
Krystal Biotech Inc (KRYS) trades at $312.88, on a P/E of 42.6x and a P/S of 22.5x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Krystal Biotech Inc overvalued?
Krystal Biotech Inc carries a Smart Value Score of 65/100 (Grade B), which we rate Buy. That score blends growth, quality, and valuation into one read.
What is the price target of Krystal Biotech Inc (KRYS)?
The 12-month analyst consensus target is $324.11, about 3.6% above the current $312.88. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is the future stock price of KRYS by 2030?
Our research-backed model puts the 2030 base case at $681.52, built from revenue projections, a growth-adjusted P/S multiple, net debt, and share dilution. It is a scenario rather than a prediction, and the bull and bear cases around it matter more than the single number when you are sizing a position.
What is Krystal Biotech Inc's revenue?
Krystal Biotech Inc's trailing twelve-month revenue is $417.30M, and our model projects it reaching about $1.43T by 2030. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
Krystal Biotech Inc's Altman Z-Score is 8.02, which places it in the safe zone. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio22.46x
ROE17.63%
Beta0.53
50D MA$288.29
200D MA$240.48
Shares out0.03B
Float0.02B
Short ratio—
Avg volume0.3M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—